Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway

26 Sept 2018

Abstract excerpt

BACKGROUND: In colorectal cancer, CDX2 expression is lost in approximately 20% of cases and associated with poor outcome. Here, we aim to validate the clinical impact of CDX2 and investigate the role of promoter methylation and histone deacetylation in CDX2 repression and restoration. METHODS: CDX2 immunohistochemistry was performed on multi-punch tissue microarrays (n = 637 patients). Promoter methylation and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Digestive system and related health
Share to Epigenetics and DNA Methylation
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30257705
DOI: 10.1186/s13148-018-0548-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathwayPMID 30257705Read ↗

Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.Semantic proximity Read ↗

Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal CancerSemantic proximity Read ↗

Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.Semantic proximity Read ↗

Methylation of CDX2 as a Predictor in Poor Clinical Outcome of Patients with Colorectal CancerSemantic proximity Read ↗

The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practiceSemantic proximity Read ↗

Decitabine treatment demethylates vast majority of high-confidence differentially methylated regions in HCT-116 colorectal cancer cellsSemantic proximity Read ↗

The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review.Semantic proximity Read ↗

Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20.Semantic proximity Read ↗

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.Semantic proximity Read ↗

Silencing of CDX2 expression in colon cancer via a dominant repression pathway.Semantic proximity Read ↗

CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal CarcinomaSemantic proximity Read ↗

Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.